A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines
Joep J. de Jong(Erasmus MC Cancer Institute), Yair Lotan(Southwestern Medical Center), Ellen C. Zwarthoff(Erasmus MC), Wim Van Criekinge(Ghent University Hospital), Kim E.M. van Kessel(Erasmus University Rotterdam), Joost L. Boormans(Erasmus MC), Olga M Pijpers(Erasmus MC Cancer Institute)
Cited by 6
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.
|Proceedings of the National Academy of Sciences|1989|493
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471